New insider activity at Crispr Therapeutics AG ( (CRSP) ) has taken place on July 17, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Director Simeon George has made a significant investment in Crispr Therapeutics AG by purchasing 989,812 shares of the company’s stock, amounting to a total value of $51,499,918.
Recent Updates on CRSP stock
Crispr Therapeutics AG recently announced an update on their clinical study evaluating the safety and efficacy of CTX131, a CRISPR-Cas9-engineered T cell treatment for hematologic malignancies. This development could positively impact the company’s stock by demonstrating progress in their innovative treatment pipeline. However, Clear Street analyst Bill Maughan downgraded the stock from Buy to Hold, citing valuation concerns as the stock approached the price target. The analyst expressed skepticism about the commercial viability of Crispr’s ex vivo gene editing approach, particularly the sluggish launch of Casgevy, indicating that the company’s pipeline has not advanced sufficiently to overcome these challenges.
Spark’s Take on CRSP Stock
According to Spark, TipRanks’ AI Analyst, CRSP is a Neutral.
The overall stock score reflects a mixed outlook. While the company faces significant financial challenges, strong technical indicators and recent corporate developments offer promising growth potential. The negative valuation metrics indicate ongoing operational struggles, but strategic partnerships could drive future performance improvements.
To see Spark’s full report on CRSP stock, click here.
More about Crispr Therapeutics AG
YTD Price Performance: 33.09%
Average Trading Volume: 2,706,632
Technical Sentiment Signal: Buy
Current Market Cap: $4.55B